ArticleEuropean geriatric medicine2025
The relationship of cytomegalovirus with physical functioning and health-related quality of life in older adults.
Article in European geriatric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytomegalovirus in HIV: A Modifiable Driver of Inflammation, Frailty, and Aging.Current HIV/AIDS reports · 2026Review
- Assessment of Active Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Infections and Patient Reported Fatigue in Ovarian Cancer Survivors.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
AIMS/
introductionCytomegalovirus (CMV) is a highly prevalent virus, known to be associated with cardiovascular morbidity. It has been hypothesised to play a role in the development of frailty, but its association with physical function and sarcopenia has yet to be fully understood. This study aimed to look at the relationship between CMV, sarcopenia and health-related quality of life in older adults.
methods210 people in the south of England, UK, with median age 68 years (49% male, 51% female) underwent demographic and medical questionnaires, measures of body composition (bioimpedance analysis), handgrip strength and the short form 36 item survey of quality of life (SF36). All participants had CMV serology and inflammatory markers measured. Measures of sarcopenia were calculated using European Working Group definitions.
results51.7% of participants were positive for CMV Immunoglobulin G (IgG). There were no significant differences between CMV positive and negative groups in age, gender, measures of sarcopenia or inflammatory markers. CMV positive groups had lower scores in all domains of the SF36, with significantly lower physical function score (88.7 vs 81.3, p = 0.003) as well as limitations due to physical health, energy/fatigue, social functioning and pain. On linear regression, CMV status was significantly associated with SF36 physical function score (p = 0.004) after adjustment for age, gender, body mass index, C-reactive protein and handgrip strength.
conclusionsCMV positivity is significantly associated with physical function and health-related quality of life in older adults, although its direct relationship to sarcopenia is yet to be fully ascertained.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.